New test drug may inhibit Alzheimer's protein
In a survey conducted by the research laboratory A new drug was discovered that could inhibit senile plaques in the brain that would lead to Alzheimer's. The results were published in the journal " Science Translational Medicine ."
The large accumulation of beta-amyloid protein is known to be one of the factors that lead to disease, creating plaques in the brain. The new drug, called verubecestat, works to reduce these plaques, acting directly on the enzyme BACE1, responsible for the appearance of beta-amyloid. Preliminary tests, performed with 32 patients, showed a reduction of up to 80% in levels of this protein. This is not the first time they have tried to create a drug with this function, but so far, all drugs created have had serious adverse effects on patients.
For the first time an oral BACE1 inhibitor drug has been authorized for a new phase involving many patients: about 3,500. Phase 3 of the research should be completed by July 2017 and, if the results remain satisfactory, the pill may be marketed within three years.
It is estimated that in the coming decades, in Brazil, the number of people over 65 will double, which will have a socioeconomic impact for which we are not yet prepared . In terms of public health, there is concern about neurodegenerative diseases, such as Alzheimer's and Parkinson's, and how to avoid them.
The fight against prejudice and discrimination is still far from over. But, increasingly, the homosexual couple leads a full life, including a right of stable union guaranteed by the Federal Supreme Court. From this fullness comes the desire to have children. Until recently, there were few alternatives.